Reference : Phase I study of single ascending doses of befloxatone, a new reversible MAO-A inhibi...
Scientific journals : Article
Social & behavioral sciences, psychology : Treatment & clinical psychology
http://hdl.handle.net/2268/259854
Phase I study of single ascending doses of befloxatone, a new reversible MAO-A inhibitor antidepressant
English
ANSSEAU, Marc mailto [Université de Liège - ULg]
Caillé, P. [Delalande Lab., France]
Derks, C. [Delalande Lab., France]
Cieren-Puiseux, I. [Delalande Lab., France]
Wauthy, J. [Psychiatric Unit, C.H.U. du Sart Tilman, B-4000 Liège, Belgium]
Ego, D. [Delalande Lab., France]
Curet, O. [Delalande Lab., France]
Thiola, A. [Delalande Lab., France]
Rovei, V. [Delalande Lab., France]
Jarreau, F. X. [Delalande Lab., France]
1992
European Neuropsychopharmacology
Elsevier
2
3
300
Yes (verified by ORBi)
International
0924-977X
1873-7862
Amsterdam
Netherlands
[en] Antidepressant ; Befloxatone ; MAOI ; Phase I study
[en] [No abstract available]
Researchers ; Professionals ; Students
http://hdl.handle.net/2268/259854
10.1016/0924-977x(92)90133-s

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Phase I study of single ascending doses of befloxatone, a new reversible MAO-A inhibitor antidepressant.pdfPublisher postprint586.06 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.